SCHEMBL3503151

SCHEMBL3503151

CON(C)C(=O)c1ccc(-n2cccn2)nc1

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.76
LMNA P02545 1/20 0.63
MEN1 O00255 1/20 0.57
KDM4E B2RXH2 5/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP2D6 P10635 1/20 0.56
ALDH1A1 P00352 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
HPGD P15428 2/20 0.54
NPSR1 Q6W5P4 1/20 0.52
CXCR4 P61073 2/20 0.47
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
SIRT3 Q9NTG7 1/20 0.40
GRN P28799 1/20 0.40
SORT1 Q99523 1/20 0.40
TACR3 P29371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437049 0.87 KMT2A (1.00) KMT2ALMNAMEN1KDM4ECYP1A2
SCHEMBL63835 0.81 LMNA (0.69) KMT2ALMNAMEN1KDM4ECYP1A2
SCHEMBL30175326 0.79 LMNA (0.75) KMT2ALMNAMEN1KDM4ECYP1A2
SCHEMBL3503653 0.79 LMNA (0.75) KMT2ALMNAMEN1KDM4ECYP1A2
SCHEMBL322839 0.78 LMNA (1.00) KMT2ALMNAMEN1KDM4ECYP1A2
SCHEMBL29425707 0.78 LMNA (1.00) KMT2ALMNAMEN1KDM4ECYP1A2
SCHEMBL15350685 0.78 KMT2A (0.46) KMT2ALMNAMEN1KDM4ECYP1A2
SCHEMBL7259823 0.77 CYP3A4 (0.52) KMT2ALMNAKDM4ECYP1A2CYP2C19
SCHEMBL4119437 0.76 LMNA (0.75) KMT2ALMNAMEN1KDM4ECYP1A2
SCHEMBL31005017 0.76 LMNA (0.75) KMT2ALMNAMEN1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193228-B2 Substituted imidazole as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-06-05 US disclosed
US-20100022598-A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME LLC 2010-01-28 US disclosed
EP-2091937-A2 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS Merck & Co., Inc. (US) 2009-08-26 EP disclosed
WO-2008051406-A2 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS MERCK & CO., INC. (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022598-A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators BRS3, INSR, INSRR KMT2A 4416/4885LMNA 1580/4885MEN1 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.